AlphAIAlphAI — Financial news for AI agents
finance.yahoo.com$ANGO

AngioDynamics (ANGO) Q1 2027 Earnings Call Transcript

AngioDynamics (ANGO) reported Q1 2027 revenue growth of 7%, with the MedTech segment up 13%. Auryon saw 14.7% growth, marking 21 consecutive quarters of double-digit gains. AlphaVac revenue rose 37.4% year-over-year. The company named Eric Honer as its new CEO, effective November 2. NanoKnife received FDA approval for a BPH study, targeting a $1.9B market. Med Device segment grew 1.4%.

Original reporting
finance.yahoo.com
Published Oct 9, 2026, 2:43 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Oct 9, 2026, 3:07 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AngioDynamics (ANGO) Q1 2027 Earnings Call Transcript — source image
Source · finance.yahoo.com
Decision brief

The 30-second read

$ANGOBullishHigh
01

Why it matters

The earnings beat and leadership change provide fresh data for traders to reassess valuation and short-term price direction.

02

Market read

First release of FY27 Q1 numbers and CEO appointment creates immediate trading relevance for ANGO and may influence medtech peers.

03

What to watch

Potential integration challenges for the new CEO and the modest decline in AngioVac sales may temper upside.

Relevance 7/10Novelty 8/10Timing: post-earnings release today

Background

AngioDynamics held its FY27 Q1 earnings call, reporting $80.9M revenue, 13.2% medtech growth, FDA approval for NanoKnife relief study, and announced Eric Honer as new CEO effective Nov 2.

Company-level read

Ticker impact

$ANGOBullishHigh confidence
Context

Q1 FY27 earnings released with revenue up 6.9% to $80.9M, medtech revenue up 13.2%, and appointment of new CEO Eric Honer effective Nov 2.

Expected impact

potential upside as investors price in earnings beat and new CEO outlook

Evidence & confidence

Revenue growth exceeds prior year and the new CEO brings extensive medtech experience, likely boosting confidence.

Market effects

Sector

Medtech segment growth may lift peer medtech stocks and reinforce sector momentum.

Regional

U.S. medtech market sees incremental demand from AngioDynamics' product launches.

Global

Limited to U.S. investors; no immediate global ripple.

Counterpoint

What could challenge this read

If earnings expectations were already high, the modest revenue increase could be seen as a miss, pressuring the stock.

Key entities

  • Company
    AngioDynamics

    Medical device manufacturer reporting FY27 Q1 results.

  • Executive
    Eric Honer

    New President and CEO effective November 2.

  • Executive
    Stephen A. Trowbridge

    EVP and CFO presenting the financial results.

Read at source← All news

StoryAngioDynamics posts Q1 FY2027 earnings beat and names new CEO

Also covered by

5 outlets

Related articles

$ANGOMed

AngioDynamics Announces Humana Medicare Advantage Coverage Policy Supporting Broader Access to NanoKnife IRE for Prostate and Liver Cancer

AngioDynamics announced that Humana updated its Medicare Advantage coverage policy to include NanoKnife IRE for prostate and liver cancer, effective October 1, 2026. This follows recent reimbursement milestones, including new CPT codes and Palmetto GBA's LCD L40205. Humana, with 7 million members, will use LCD L40205 criteria for coverage, subject to prior authorization.

marketscreener.com
$ANGOMed

H.C. Wainwright cuts AngioDynamics stock price target to $18

H.C. Wainwright reduced its price target for AngioDynamics (ANGO) to $18 from $19, maintaining a Buy rating. The company reported fiscal Q1 2027 net sales of $80.9M, up 6.9% YoY, but a net loss of $7.1M. Guidance for fiscal 2027 includes revenue of $336M-$341M and adjusted EBITDA of $13M-$16M. Canaccord Genuity reiterated its Buy rating with a $20 target, citing growth in key platforms. The stock fell 23% post-earnings.

investing.com
$ANGOMed

AngioDynamics Announces Humana Medicare Advantage Coverage Polic

AngioDynamics (ANGO) announced Humana's updated Medicare Advantage coverage policy for its NanoKnife System, effective October 1, 2026. The policy applies LCD L40205 criteria for IRE technology, covering eligible patients with intermediate-risk prostate cancer and certain liver tumors. This follows recent reimbursement milestones, including CPT codes and Palmetto GBA's LCD. Humana, with 7 million members, will use LCD L40205 criteria for consistent coverage.

gurufocus.com
$ANGOHighAI 8/10

AngioDynamics, Inc. Q1 2027 Earnings Call Summary

AngioDynamics reported Q1 2027 earnings, with MedTech segment revenue growing 13.2% YoY, now 49% of total revenue. Auryon saw 21st straight quarter of double-digit growth. NanoKnife adoption increased, with record procedure volumes. Full-year revenue guidance is $336M-$341M, with MedTech expected to dominate. Gross margin expanded 410 bps due to pricing and mix shift. Eric Honer appointed as new CEO. The company remains debt-free and expects positive cash flow for the year.

finance.yahoo.com